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Available online 14 July 2012A stimulatory effect of apigenin-6-C-β-fucopyranoside (1) on glucose uptake was observedwhen
rat soleus muscle was incubated with 1, 10 and 100 μM of this flavonoid glycoside. The presence
of specific insulin signaling inhibitors, such as wortmannin, an inhibitor of phosphoinositide
3-kinase (PI3K), RO318220, an inhibitor of protein kinase C (PKC), PD98059, an inhibitor of
mitogen-activated protein kinase (MEK), and HNMPA(AM)3, an insulin receptor tyrosine kinase
activity inhibitor showed that apigenin-6-C-β-fucopyranoside triggers different metabolic
pathways in skeletal muscle. The oral administration of crude extract, fractions and isolated
flavonoids (apigenin-6-C-β-fucopyranoside (1) and apigenin-6-C-(2″-O-α-rhamnopyranosyl)-
β-fucopyranoside (2)) from Averrhoa carambola leaves exhibited a potential hypoglycemic
activity in hyperglycemic normal rats. Additionally, both flavonoids significantly increased the
muscle and liver glycogen content after an acute treatment. The results indicate that A. carambola
can be regarded as a potent antihyperglycemic agent with insulin secretagogue and insulin
mimetic properties.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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Glucose uptake1. Introduction
Averrhoa carambola L. (Oxalidaceae), known as star fruit,
is native from tropical and subtropical regions of Asia and it
was successfully introduced to Brazil in 1817. Averrhoa
carambola (A. carambola) has been used as an appetite
stimulant, a diuretic, an antiemetic, an antidiarrheal, an
antifebrile and for the treatment of eczemas [1]. Recently, the
decoction of A. carambola leaves has been used in theica, Centro de Ciências
rianópolis, SC — Brasil.
squisador.cnpq.br
lsevier OA license.treatment of diabetes [2,3]. Other species of the Averrhoa
genus, such as Averrhoa bilimbi Linn. are known for their
anti-inflammatory, anti-scorbutic, astringent, anti-bacterial
and antidiabetic properties [4]. In addition, a leaf extract and
semi-purified fractions of A. bilimbi exhibited hypoglycemic
and hypolipidemic effects when administered intraperitone-
ally [5] as well as orally in diabetic rats [6–8].
Some plants used in popular medicine to treat diabetes have
been found to contain great amounts of flavonoids showing
potentially important antihyperglycemic action, in different in
vivo and in vitro assays, including reduction of serum glucose
levels, stimulation of insulin secretion, regulation of enzyme
activity in carbohydrate metabolism, stimulation of glucose
uptake and glycogen storage in peripheral tissues [9,10]. We
have previously demonstrated that flavonoids isolated from
1177L.H. Cazarolli et al. / Fitoterapia 83 (2012) 1176–1183A. carambola leaves, act on glucose homeostasis through
stimulating in vitro glucose uptake and glycogen synthesis.
Also, they were able to increase insulin secretion after in
vivo treatments [11,12].
Based on the potential antihyperglycemic effect reported for
flavonoids, this study was carried out to investigate the effect
and themechanism of action of apigenin-6-C-β-fucopyranoside
on 14C-glucose uptake in soleus muscle in normal rats. Also, the
acute effect of the crude extract, fractions and isolated com-
pounds from A. carambola on serum glucose levels, muscle and
liver glycogen content.
2. Materials and methods
2.1. Materials
Tolbutamide and oyster glycogen type II were pur-
chased from Sigma Chemical Company® (St. Louis, MO,
USA). The iodine reagents (CaCl2+I2+KI) were purchased
from VETEC, Rio de Janeiro, Brazil. Regular human insulin
(Biohulin) was obtained from Biobrás, Bioquímica do Brasil
S/A (Águas Claras, MG, Brazil). [U-14C]-2-Deoxy-D-glucose
(14C-DG), specific activity 10.6 GBq/mmol, D-[14C (U)]‐
glucose (14C-glucose), specific activity 9.25 GBq/mmol and
biodegradable scintillation liquid were obtained from
Perkin-Elmer Life and Analytical Sciences (Boston, MA,
USA). Wortmannin [inhibitor of phosphoinositide 3-kinase
(PI3K)], RO318220 [inhibitor of protein kinase C (PKC)],
and PD98059 [inhibitor of mitogen-activated protein kinase
(MEK)] were purchased from Sigma Chemical Company®
(St. Louis, MO, USA). HNMPA(AM)3 [inhibitor of insulin receptor
tyrosine kinase activity]was purchased fromEnzo Life Sciences®
(NY, USA). Salts and solvents were purchased from Merck AG
(Darmstadt, Germany).
2.2. Plant material
The leaves of A. carambola were collected (March, 2003;
co-ordinates −27.687799 latitude; −48.777296 longitude)
at Santo Amaro da Imperatriz, Santa Catarina, Brazil and
identified by Prof. Daniel de Barcellos Falkenberg. A voucher
specimen was deposited at the herbarium of the Botany
Department at the Universidade Federal de Santa Catarina,
Florianópolis, under number FLOR-24.144.O
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Fig. 1. Chemical structure of compounds apigenin-6-C-β-fucopyranoside (com
(compound 2) isolated from the EtOAc fraction of A. carambola leaves.2.3. Extraction and isolation
The powdered, dried leaves (281 g) were extracted with
ethanol–water (EtOH-H2O) (4:1). The extract was concentrated
to dryness by rotatory vaporization at 60 °C under reduced
pressure (41.3 g; crude extract-dry leaves ratio=14.7%). The
concentrated extractwas then suspended in EtOH-H2O (4:1) and
successively extracted with n-hexane, ethyl acetate (EtOAc) and
n-butanol (n-BuOH). The ethyl acetate soluble fraction (EtOAc)
of 6.9 g was subjected to silica gel (100–200 mesh) CC and
eluted with an ethyl acetate/ethanol mixture gradient to afford
36 fractions. Fractions 6–8 (150 mg) and 10–12 (200 mg) were
purified by recrystallization frommethanol (MeOH) to give pure
(HPTLC in ethyl acetate/methanol/acetic acid 80:14:6 and NMR)
compounds 1 and 2, respectively. These compounds were
identified by nuclear magnetic resonance spectroscopy (NMR)
analysis (1H, 13C, DEPT, COSY, HMQC and HMBC) and compar-
ison with literature data [13].
Apigenin-6-C-β-fucopyranoside (compound 1): Yellow
amorphous powder, (drug-extract ratio=0.36%). 1H NMR
(400 MHz, CD3OD): aglycone moiety δ: 6.61 (s, H-3), 6.53 (s,
H-8), 7.84 (d, J=8,0 Hz, H-2′ & H-6′), 6.92 (d, J=8,0 Hz, H-3′ &
H-6′); sugarmoiety: 4.64 (d, J=8.4 Hz, H-1″), 4.03 (t, J=8.7 Hz,
H-2″), 3.97 (dd, J=3.0 and 6.5 Hz, H-3″), 3.50 (d, J=3.0 Hz,
H-4″), 3.17 (m, H-5″), 1.44 (d, J=6.2 Hz, H-6″).13C NMR
(400 MHz, CD3OD) aglycone moiety δ: 165.1 (C-2), 99.6 (C-3),
183.1 (C-4), 161.7 (C-5), 108.0 (C-6), 163.9 (C-7), 94.0 (C-8),
161.8 (C-9), 102.8 (C-10), 121.9 (C-1′), 128.3 (C-2′ and 6′),
115.9 (C-3′ and 5′), 157.8 (C-4′); sugarmoiety: 71.9 (C-1″), 69.1
(C-2″), 78.5 (C-3″), 70.6 (C-4″), 70.8 (C-5″), 18.1 (C-6″).
Apigenin-6-C-(2″-O-α-rhamnopyranosyl)-β-fucopyranoside
(compound 2): Yellow amorphous powder (drug-extract
ratio=0.48%). 1H NMR (400 MHz, CD3OD): aglycone moiety
δ: 6.61 (s, H-3), 6.54 (s, H-8), 7.85 (d, J=7.6 Hz, H-2′ and H-6′),
and 6.94 (d, J=7,6 Hz, H-3′ and H-6′); sugar moieties: 4.91 (d,
J=9.6 Hz, H-1″), 4.27 (t, J=8.8 Hz, H-2″), 3.75 (m, H-3″), 3.69
(sl, H-4″), 3.84 (m, H-5″), 1.28, (d, J=6.0 Hz, H-6″), 5.18 (sl,
H1‴), 3.78 (sl, H-2‴), 3.28 (overlapped with signals of CD3OD,
H-3‴), 3.09 (t, J=9.5 Hz, H-4‴), 2.54 (t, J=8.4 Hz, H-5‴), and
0.71 (d, J=6.0 Hz, H-6‴). 13C NMR (400 MHz, CD3OD) aglycone
moiety δ: 165.1 (C-2), 104.3 (C-3), 183.0 (C-4), 161.6 (C-5),
108.8 (C-6), 163.0 (C-7), 95.0 (C-8), 159.6 (C-9), 102.8 (C-10),
122.0 (C-1′), 128.3 (C-2′ and 6′), 115.9 (C-3′ and 5′), and 157.7
(C-4′); sugarmoieties: 72.2 (C-1″), 75.1 (C-2″), 76.5 (C-3″), 72.8O
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pound 1) and apigenin-6-C-(2″-O-α-rhamnopyranosyl)-β-fucopyranoside
Table 1
Acute effect of lispro insulin, tolbutamide and crude extract of A. carambola on the serum glucose level in the oral glucose tolerance curve.
Time
Group I Group II Group III Group IV
Vehicle Hyperglycemic glucose Hyperglycemic plus tolbutamide Glucose fed hyperglycemic plus A. carambola crude extract
(min) (1% EtOH-H2O) (4 g/kg) (100 mg/kg) 200 mg/kg 400 mg/kg 800 mg/kg
0 111.8±2.8 122.6±5.8 108.4±5.1 110.1±3.3 111.8±5.7 125.4±7.8
15 114.7±6.8 196.2±13.6*** 168.6±5.6*** 178.4±8.7*** 174.7±7.3*** 172.0±2.8***
30 125.5±3.8 201.7±11.9*** 172.0±10.4***# 184.4±7.6*** 167.8±7.3***# 182.2±5.8***
60 128.3±3.8 178.4±9.1*** 145.8±6.8# 147.5±5.6**# 153.2±5.9***# 165.9±8.9**
120 120.1±6.9 137.8±7.7 131.8±9.5 138.4±6.0 139.8±5.2 151.8±6.7
180 120.7±2.0 134.3±4.4 131.8±6.9 144.1±4.2* 149.5±4.1** 140.4±6.0
Values expressed as mean±S.E.M.; n=6 in duplicate for each treatment. Statistically significant difference to the corresponding zero time value; *p≤0.05;
**p≤0.01; ***p≤0.001. Significantly different to the corresponding hyperglycemic group; # p≤0.05.
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(C-3‴), 72.4 (C-4‴), 68.7 (C-5‴), and 16.8 (C-6‴) (Fig. 1).2.4. Experimental animals
MaleWistar rats (190–220 g)were used. Theywere bred in
our animal facility and housed in an air-conditioned room
(approximately 22±2 °C and during the entire experiments)
with controlled lighting on a 12:12 h light/dark cycle (lights on
from 06:00 to 18:00 h). The animals were maintained with
pelleted food (Nuvital, Nuvilab CR1, Curitiba, PR, Brazil), while
tap water was available ad libitum. For all oral treatments,
0.5 mL of each respective substance was given by gavage.
Animals described as fasted had been deprived of food for 16 h
but allowed free access to water [14]. All the animals were
monitored carefully and maintained in accordance with the
ethical recommendations of the Brazilian Veterinary Medicine
Council and the Brazilian College of Animal Experimentation.
(Protocol CEUA/PP007).2.5. Determination of the serum glucose level
Blood samples (100 μL) were collected from the tail vein
of the anesthetized rat, centrifuged and the serum was used
to determine the glycemia (GBC 916 UV–visible spectropho-
tometer) by the glucose oxidase method [15]. The commercialTable 2
Acute effect of EtOAc and n-BuOH fractions of A. carambola on the serum glucose le
Time
Group I Group II Group
Vehicle Hyperglycemic glucose Gluco
A. cara
(min) (1% EtOH-H2O) (4 g/kg) 400 m
0 111.8±2.8 122.6±5.8 108.3±
15 114.7±6.8 196.2±13.6*** 135.6±
30 125.5±3.8 201.7±11.9*** 163.1±
60 128.3±3.8 178.4±9.1*** 131.3±
120 120.1±6.9 137.8±7.7 113.0±
180 120.7±2.0 134.3±4.4 102.8±
Values expressed as mean±S.E.M.; n=6 in duplicate for each treatment. Statistic
Significantly different to the corresponding hyperglycemic group; # p≤0.05; ## p≤kit used to determine the glycemia was from Gold Analisa
(Belo Horizonte, MG, Brazil).
2.6. Study of the effects of crude extract, fractions or isolated
compounds from A. carambola on the serum glucose level in the
oral glucose tolerance curve
Fasted rats were divided into groups of six animals for each
treatment: Group I, normal rats that received vehicle 1%
EtOH-H2O; Group II, hyperglycemic rats that received glucose
(4 g/kg) plus vehicle; Group III, hyperglycemic rats that
received glucose (4 g/kg) plus tolbutamide (100 mg/kg b.w.)
by oral gavage; Group IV, rats that received glucose (4 g/kg)
plus crude extract (200, 400 and 800 mg/kg b.w.) (Table 1). As
shown in Table 2, the hyperglycemic rats received EtOAc or
n-BuOH (400 and 800 mg/kg b.w.) fractions. Also, hyperglyce-
mic rats received isolated compounds 1 or 2 (20 and 50 mg/kg
b.w.) by oral gavage (Fig. 2). Blood samples were collected just
prior to and at 15, 30, 60, 120 and 180 min after the glucose
loading and the serum glucose levels were measured.
2.7. Studies on glycogen content
Soleus muscles and livers were harvested from normal fed
or fasted rats and hyperglycemic rats treated with com-
pounds 1 or 2 (50 mg/kg) or regular insulin (0.5 IU) and used
for the assay of glycogen content immediately after 3 h ofvel in the oral glucose tolerance curve.
III Group III
se fed hyperglycemic plus
mbola EtOAc fraction
Glucose fed hyperglycemic plus
A. carambola n-BuOH fraction
g/kg 800 mg/kg 400 mg/kg 800 mg/kg
3.1 108.2±3.9 134.2±5.4 126.6±3.6
5.0## 152.4±9.3# 178.4±5.7 169.2±7.1
5.3## 167.8±9.2# 178.7±5.4 162.2±6.6#
6.6## 166.5±5.8 150.0±4.9# 148.5±6.2#
4.8## 142.7±4.9 173.0±5.9 129.5±4.7
6.1## 130.0±4.3 172.0±4.4 126.2±2.6
ally significant difference to the corresponding zero time value; ***p≤0.001.
0.01.
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Fig. 2. Effect of compound 1 and compound 2 isolated from A. carambola on the oral glucose tolerance curve. Values are expressed as mean±S.E.M; n=6 in
duplicate for each treatment. Statistically significant difference to the corresponding hyperglycemic group; *p≤0.05; **p≤0.01.
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tissues as described by Krisman, 1962 [16] with minor
modifications. The tissues were weighed, homogenized in
33% KOH and boiled at 100 °C for 20 min, with occasional
stirring. After cooling, 96% ethanol was added to the samples
and heated to boiling followed by cooling in an ice bath to aid the
precipitation of glycogen. The homogenates were centrifuged
at 1300×g for 15 min, the supernatant was discarded and
the pellets were neutralized with saturated NH4Cl before
being heated to 100 °C for 5 min, washed and resolubilized
in water. Glycogen content was determined by treatment
with iodine reagent and the absorbance was measured at
460 nm. The results were expressed as mg of glycogen/g of
tissue.
2.8. Studies on 14C-glucose uptake in rat soleus muscle
For the [U-14C]-2-deoxy-D-glucose uptake experiments,
soleus muscles from normal rats were used. Slices of soleus
muscle were distributed (alternately left and right) between
basal and treated groups. Themuscles were dissected, weighed,
and preincubated and incubated at 37 °C in Krebs Ringer-
bicarbonate (KRb) buffer with a composition of 122 mM NaCl,
3 mM KCl, 1.2 mMMgSO4, 1.3 mM CaCl2, 0.4 mM KH2PO4, and
25 mM NaHCO3 and bubbled with O2/CO2 (95%:5%, v/v) until
pH 7.4. Apigenin-6-C-β-fucopyranoside (compound 1) (1, 10,
100 μM) and insulin (10 nM) were added to the preincubation
(30 min) and incubation media (60 min) in the presence or
absence of 100 nM wortmannin, 40 μM RO318220 or 50 μM
PD98059. 14C-DG (0.1 μCi/mL) was added to each sample
during the incubation period. After incubation, the musclesamples were homogenized in 0.5 N NaOH and boiled for
10 min; 25 μL aliquots of tissue and external medium were
placed in scintillation liquid on an LKB RackBeta liquid
scintillation spectrometer (model 1215; EG and G-Wallac,
Turku, Finland), for the radioactivity measurements. The results
were expressed as the tissue/medium (T/M) ratio: cpm/mL
tissue fluid per cpm/mL incubation medium [14].
2.9. Data and statistical analysis
Data were expressed as mean±S.E.M. One-way analysis
of variance (ANOVA) followed by Bonferroni post-test or
unpaired Student's t-test was used to identify significantly
different groups. Differences were considered to be signifi-
cant at p≤0.05. The software InStat version 3.05; Graph-Pad
Software Inc., San Diego, CA was used for statistical analysis.
3. Results
3.1. Effect of tolbutamide, crude extract, EtOAc, n-BuOH fractions
or apigenin-6-C-β-fucopyranoside and apigenin-6-C-(2″-O-α-
rhamnopyranosyl)-β-fucopyranoside from A. carambola on the
oral glucose tolerance curve
As expected, after starting the glucose tolerance test in
normal rats overloaded with glucose, the serum glucose
concentration was significantly increased when compared
with the zero time of this group. The oral hypoglycemic
agent, tolbutamide (100 mg/kg), produced a typical serum
glucose lowering at 30 and 60 min compared to the
hyperglycemic group. The normal vehicle control group
1180 L.H. Cazarolli et al. / Fitoterapia 83 (2012) 1176–1183(1% EtOH-H2O) showed an unchanged profile of glycemia
over the time studied (Table 1).
Crude extract at 200 and 400 mg/kg was effective in
reducing glycemia at 30 min and/or 60 min after oral treatment
when compared with the respective hyperglycemic control
group. Furthermore, oral treatment with 400 mg/kg of the
EtOAc fraction in hyperglycemic rats produced a significant
antihyperglycemic effect from 15 to 180 min (Table 2). In
addition, the glycemiawasmaintained at basal levels from 60 to
180 min (Table 2). On the other hand, the 800 mg/kg dose
showed a fast antihyperglycemic effect only in the first two
periods studied (15 and 30 min) (Table 2). Table 2 shows the
effect of the n-BuOH fraction of A. carambola at 400 and
800 mg/kg in hyperglycemic animals. Although both doses
showed a slightly antihyperglycemic effect (at 60 or 30 min
and 60 min, respectively) neither 400 nor 800 mg/kg doses
were as powerful as the EtOAc fraction (400 mg/kg), previ-
ously demonstrated in Table 2.
The oral administration of compound 1 reduced serum
glucose levels in hyperglycemic rats and the maximum
reduction observed was 19% at 15 min with the higher dose
(Fig. 2B). The effect of compound 2 on the glucose tolerance
curve was similar and is shown in Fig. 2C and D. Oral
administration with 20 and 50 mg/kg of this compound0
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Fig. 3. Effect of compound 1 and compound 2 on the glycogen content in
normal hyperglycemic rats. (A) soleus muscle and (B) liver 3 h after treatment
by oral gavage. Values are expressed as mean±S.E.M; n=6 in duplicate for
each group. Significantly different to the corresponding fasted normal group;
*p≤0.05; **p≤0.01; ***p≤0.001.significantly reduced the glycemia by around 32%, 24% and
16% at 15, 30 and 60 min, respectively, after treatment with
the higher dose used. At 120 and 180 min, glycemic levels
were similar to respective results for the hyperglycemic
control groups.3.2. Effect of apigenin-6-C-β-fucopyranoside and apigenin-6-C-
(2″-O-α-rhamnopyranosyl)-β-fucopyranoside from A. carambola
on the glycogen content of soleus muscle and liver
Fig. 3A and B shows that the glycogen content was
significantly increased, 3 h after the administration of glucose
(4 g/kg) by oral gavage, in soleus muscle compared with fed
and fasted normal rats and in liver when comparedwith fasted
normal rats. In addition, the well known insulin stimulatory
effect on glycogen storage in both tissues was observed 3 h
after insulin treatment in hyperglycemic normal rats compared
with fasted and hyperglycemic normal rats.
Compound 1was able to significantly increase the glycogen
content in soleus muscle when compared with fed normal (4.6
times), fasted normal (10.7 times), hyperglycemic (1.2 times)
and hyperglycemic plus insulin (1.14 times) animals 3 h after
treatment. Moreover, compound 1 stimulated glycogen content
in the liver as well. This change was 25 times when comparedA
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action of 100 μM compound 1 (B) on 14C-glucose uptake in rat soleus muscle.
Preincubation time=30 min; incubation time=60 min. Values are expressed
as mean±S.E.M.; n=6 in duplicate for each group. Significant at ***p≤0.001,
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represented 54% of the insulin stimulatory effect.
The stimulatory effect of compound 2 on muscle glycogen
content (around 1.7 and 3.9 times) was observed 3 h after
treatment when compared with fed and fasted groups,
respectively. However, compound 2 did not alter the glycogen
content as compared with hyperglycemic group. In the liver,
the effect of compound 2 was around 10-fold when compared
with fasted normal rats and when compared with insulin,
representing 21% of the total stimulatory effect of the hormone.3.3. Effect of apigenin-6-C-β-fucopyranoside from A. carambola
and insulin on 14C-glucose uptake in the rat soleus muscle
Fig. 4A shows the in vitro effect of compound 1 (1, 10 and
100 μM) and insulin (10 nM) on glucose uptake in the rat soleus
muscle following 60 min of incubation. As expected, insulin
stimulated significantly the 14C-DG uptake when compared to
the control group. The stimulatory effect of compound 1 was
significant at 1, 10 and 100 μMand represented 14.2, 14 and 25%
of glucose uptake compared to the basal value at 60 min,
respectively.
Taking into account the effect of compound 1 on glycemia
and on glycogen synthesis, we investigated whether the
action of compound 1 on glucose uptake also involves the
insulin signaling pathways. To do this, we performed the
glucose uptake assays in the presence of specific inhibitors of
insulin signaling. As observed in Fig. 4B, the stimulatory effect of
compound 1was completely blocked in the presence of 100 μM
of HNMPA(AM)3 [17–19]. Additionally, the pretreatment
of the muscle with wortmannin (PI3K inhibitor), RO318220
(atypical PKCs inhibitor) and PD98059 (MEK inhibitor)
completely blocked the compound 1-induced glucose uptake
(Fig. 5).4. Discussion
Flavonoids are a large group of phenolic plant constituents
and their bioactive potential in the treatment and prevention of
diabetes and other diseases has been demonstrated [9,10].
They can affect glucose transport andmetabolism in peripheral
tissues as well as inducing insulin release from β-cells in the
pancreas [14,15,20]. This study showed the antihyperglycemic
effect of the crude extract, fractions and isolated compounds of
A. carambola leaves in normal hyperglycemic rats following an
acute treatment. Also it was demonstrated the stimulatory
effect of apigenin-6-C-β-fucopyranoside (compound 1) on
glucose uptake in an insulin target, soleus muscle.
Several plants rich in flavonoids have been shown to have
an effect on blood glucose levels. Similar results showing the
glucose lowering effects of the crude extract of A. carambola
leaves in hyperglycemic normal rats were reported by
Provasi et al. [2]. Also, it has been reported in the literature
that the extracts of another Averrhoa species, A. bilimbi,
showed antihyperglycemic effect in normal hyperglycemic
and diabetic rats when compared with the respective control
groups [6,7]. Furthermore, acute treatment with Syzygium
cordatum leaf extracts has been found to decrease serum
glucose levels in hyperglycemic rats compared to a control
group. In addition, the crude extracts from the roots and
leaves ofWilbrandia ebracteata has shown significant activity
in glucose-hyperglycemic rats [21,22]. The EtOAc and
n-BuOH fractions were isolated from the crude extract and
their potential antihyperglycemic effects were studied in
normal glucose-fed rats. The antihyperglycemic effect of the
EtOAc fraction was more marked than that of n-BuOH at
400 mg/kg and was around 26.4% at 60 min after treatment
(Table 2). This effect was as pronounced as that caused by
tolbutamide (18.26%) (Table 1), a sulfonylurea agent that
increases insulin secretion from the pancreas [23]. In line
with these results, previous studies of Pushparaj et al. [7] and
Tan et al. [8] showed the effect of aqueous and n-BuOH
fractions from A. bilimbi leaves on glucose serum levels in
diabetic and hyperglycemic normal rats. Both fractions
improved the glucose tolerance curve in diabetic rats and
hyperglycemic rats. Furthermore, after two weeks of treat-
ment the fractions increased plasma insulin levels when
compared with the zero time and with the diabetic control
group.
Considering the EtOAc fraction's antihyperglycemic effect,
two glycosylated flavonoids, compound 1 and compound 2
(C-flavones) were isolated from this fraction. Both flavonoids
were previously demonstrated to act through at least two
different mechanisms, stimulating insulin secretion from the
pancreas and interacting with classical cellular insulin metabolic
signaling [11,12]. The oral administration of compounds 1 and 2
at 20 and 50 mg/kg resulted in significant antihyperglycemic
effects in glucose-fed normal rats. Recently, Hsu et al. [24]
demonstrated the antihyperglycemic effect of puerarin, an
isoflavone, in normal rats, hyperglycemic normal rats and
diabetic rats. Puerarin reduced glycemia in normal and diabetic
rats in a dose dependent manner and it was also able to
attenuate the increase of plasma glucose induced by an
intravenous glucose challenge in normal rats.
The antihyperglycemic effect of fractions from Cephalotaxus
sinensis leaves were evaluated in streptozotocin (STZ)-induced
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identified from the most active fraction, apigenin-5-O-[α-L-
rhamnopyranosyl-(1→4)-6-O-β-D-acetylglucopyranoside],
apigenin and apigenin-5-O-[α-L-rhamnopyranosyl-(1→4)-6-
O-β-D-glucopyranoside]. These flavonoids were shown to
significantly increase the GLUT-4 protein level in membrane
preparations from mice adipocytes which could contribute
to the effect of C. sinensis on glucose homeostasis [25]. We
have demonstrated the antihyperglycemic effect of the EtOH
fraction, rich in glycosylated flavonoids, from Bauhinia
forficata leaves as well as themajor flavonoid of that fraction,
kaempferitrin [26,27]. Recently, the flavonoid rich fraction
of Pilea microphylla, constituted mainly by apigenin-7-O-
glucoside, quercetin, rutin and luteolin-7-O-glucoside was
shown to improve oral glucose tolerance in normal and
STZ-diabetic rats [28]. Also, the antihyperglycemic activity
of plant extracts rich in flavones in hyperglycemic and
diabetic rats has been described [29,30]. The n-butanol
fraction and the methanol subfraction from W. ebracteata
and the C-glycosylflavones isovitexin and swertisin showed
a potent antihyperglycemic action when compared with the
crude extract and with the controls and this effect seems to
be mediated through insulin secretion from the pancreas
[22].
Recently, the flavonoids apigenin and apigenin-7-O-
glucoside showed an antihyperglycemic effect and also reduced
the glycemia of streptozotocin induced-diabetic rats after 7 days
of treatment [31]. Furthermore, it has been demonstrated that
apigenin had a protective effect on pancreatic β‐cell destruction
in a model of Sterptozotocin-induced diabetes and significantly
increased insulin release [32]. The results observed in vivo for
compounds 1 and 2 may be due to the stimulus of pancreatic
function such as the insulin secretion as well as their action as
insulin mimetic agents as previously proposed [11,12].
In mammals, carbohydrate is stored mainly in the form of
glycogen, with skeletal muscle and liver as the major storage
sites. Glycogen metabolism is regulated by insulin/glucagon
through activation and/or inhibition of several enzymes and
proteins [33]. The determination of glycogen levels in muscle
and liver of hyperglycemic normal rats after acute treatments
with compounds 1 and 2 revealed a significant increase in
glycogen content when compared with fasted normal rats
(Fig. 3A and B). Additionally, the known effect of insulin on
muscle and hepatic glycogen storage was observed. The study
demonstrated that the stimulatory effect of compound 1 on
glycogen storage in soleusmuscle aswell as in liverwas greater
than that of compound 2 at the same dosage (50 mg/kg). Such
an effect of compound 1 was quite similar to that of insulin in
muscle. Also, we demonstrated that compound 1 stimulated
glucose uptake in soleus muscle and this effect was mediated
through the classical insulin signaling since in the presence of
specific insulin signaling inhibitors (PI3-K, atypical PKCs and
MEK) the stimulatory effect of the flavonoid was completely
abolished.
Flavonoids and plant extractswith proven antihyperglycemic
activity have been shown to influence glucose uptake, glycogen
synthesis and glycogen deposition in different tissues as well as
to interact with key enzymes of the glycolytic route in rats
[14,34].We have demonstrated that both flavonoids from
A. carambola are able to increase insulin secretion and to
influence glucose disposal acting through insulin signalingand increasing glucose uptake and glycogen synthesis in
soleus muscle. Furthermore, Zanatta et al. [35] showed that
kaempferol 3-neohesperidoside, a flavonol isolated from
Cyathea phalerata, increased muscle glycogen content in
diabetic rats and stimulated glucose uptake in normal rats.
The results found for compound 2 and especially for compound
1 (Figs. 2 and 3) are closely correlated with the known insulin
activity on the stimulatory effect of glucose disposal and
lowering serum glucose levels in normal hyperglycemic rats
(Fig. 3). As previously shown and in the present study we can
propose that the in vivo effect of crude extract, fractions and
isolated compounds from A. carambola is a consequence of
direct peripheral glucose uptake, glycogen synthesis and
insulin secretion or a combination of both.
5. Conclusions
We have shown that apigenin-6-C-β-fucopyranoside was
able to increase glucose uptake in soleus muscle acting
through insulin signaling pathways such as insulin receptor
tyrosine kinase activity, PI3K, atypical PKCs and MEK. Also,
both flavonoids reduced serum glucose levels after acute
treatments being able to manage glucose utilization through
different pathways. In conclusion, our results indicate that
A. carambola should be regarded as a potent antihyperglycemic
agentwith insulin secretagogue and insulinmimetic properties
being an attractive adjuvant for the treatment of diabetic
patients in the future.
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